Proportion of CD34+CD38−CD123+ Leukemia Stem Cells at Diagnosis Varies in ELN Risk Groups and an Emerging Novel Marker for Prognosticating the Intermediate Risk patients of Acute Myeloid Leukemia: A Prospective Study
暂无分享,去创建一个
R. Saxena | H. Pati | M. Mahapatra | S. Tyagi | P. Mishra | R. Sharma | Rohan Halder | Rahul Sharma